William (Dongfang) Shi, Ph.D.
CEO, President, Chairman, & Founder
Dr. Shi started Atom Bioscience in March of 2012. He has served as Chief Executive Officer, President and Chairman since January of 2015. Previously, he had served as our Chief Executive Officer and President since March of 2012. From 1999 to 2011, Dr. Shi served in various positions of increasing responsibility at Genelabs Technologies Inc. and Metabolex Inc. He has worked on the new drug discovery and development on the area of anti-cancer, HCV, diabetes, gout, and NASH for more than 28 years. He was leading the new drug design, organic synthesis, patent application, preclinical studies, clinical trials, financing, ect. Dr. Shi authored 43 patents and 26 of them were from Atom Bioscience. He published 13 peer reviewed papers from his Ph.D. and postdoctoral work. Dr. Shi received his Ph.D. in Medicinal and Organic Chemistry from the University of Nottingham in 1995, and was the Postdoctoral Fellow in Medicinal Chemistry at the University of Texas at Austin from 1996 to 1998.
Marc Gurwith，M.D. & J.D.
Chief Medical Officer
Dr. Gurwith joined Atom Bioscience in August of 2018 as our Chief Medical Officer. Previously, he was Executive Vice President, Scientific Affairs at PaxVax Inc. in 2017. From 2007 to 2017, Dr. Gurwith served as Chief Medical Officer at PaxVax. From 2001 to 2007, he was Senior Vice President, Medical Affairs, and Chief Medical Officer at VaxGen, Inc. From 1997 to 2001, Dr, Gurwith served as Vice President of Drug Development and Chief Medical Officer at Genelabs Technologies. Inc. In his previous career, Dr. Gurwith was an Associate Professor of Medicine at University of Kansas School of Medicine, UCLA, and Michigan State University. He was Vice President of Clinical Research at Sequus Pharmaceuticals. Dr. Gurwith obtained his M.D. from the Harvard University, Medical School and his B.A. from the Yale University. He did his Medical Resident at the Stanford University, School of Medicine. He also received his J.D. from the Temple University School of Law.
Roy J. Wu, MBA
Senior Vice President, Global Business Development
Mr. Wu joined Atom Bioscience in August of 2019 as Senior Vice President, Global Business Development. Previously, he was our Senior Consultant in Business. From 2009 to 2016, Mr. Wu served as Senior Vice President, Business Development at Novabay Pharmaceuticals Inc. From 2001 to 2009, Mr. Wu was Vice President, Business Development at Genelabs Technologies Inc. From 1997 to 2001, Mr. Wu served as Vice President, Business Development at Kissei Pharma (USA) Inc. From 1989 to 1995, Mr. Wu served as Director, R&D Program Planning and Management Japan and Pacific Sector at Syntex Corporation. Mr. Wu had 35 years of successful experience of Business Development, Licensing, Distributor Management, International Marketing, Project Management, Clinical Development, Pacific Sector Regulatory and Pharmaceutical Development. Areas of expertise include Product licensing, technology collaboration and alliance management; Strategic Planning for Business Unit; International Marketing, New Product Planning; International Project Management and Clinical Development; U.S. and Japan drug development experience in GI, CV, analgesic, urology, immunology and metabolic disease; Regulatory experience with FDA (USA), PMDA (Japan), CFDA (China), TFDA (Taiwan), MFDA (S. Korea) for Drugs and Medical Device. Mr. Wu received his MBA, International Finance from the University of San Francisco, School of Business, and B.S. in Biology from the University of San Francisco.
Senior Director, Clinical Operation & Data Management
Dr. Farling joined Atom Bioscience team in August of 2018 as Senior Director, Clinical Operation and Data Management. Previously, Dr. Farling served as Director and Senior Director of Clinical Operations, Senior Clinical Trial Manager, as well as Clinical Study Monitor (Consultant) for various pharmaceutical companies such as Vaxart, Inc., Portola Pharmaceuticals, Inc., Horizon Pharma, KangLaiTe-USA, Inc., Zogenix, Inc., CV Therapeutics, Inc., Guidant Corporation, Kanglaite-USA, Inc., Galileo Laboratories, Inc., and Centaur Pharmaceuticals, Inc. Her areas of expertise include management of the clinical studies and operations services, data collection and management, review of monitoring reports, preparation of protocol/amendments, study training documents, eCRF, site training and initiation, ect. Dr. Farling has 20 years experience in Clinical Research and Operations from Phase 1 to Phase 3. Dr. Farling received her Ph.D. in Biochemistry from the State University of New York, and did her Postdoctoral Fellow at Albert Einstein College of Medicine.
Adam (Wenqing) Jin, M.S.
Vice President, China Business Development and Human Resources
Mr. Jin has served as Vice President, China Business Development and Human Resources since July 2015. He is responsible for project collaboration, equity financing activities, and license agreements. Mr. Jin assisted in the completion of Round A and Round A+ financing. Prior to joining Atom Bioscience, he was Project Manager at Sterile Technology LLC, where he was responsible for process development, GMP validation and operation consulting. Mr. Jin obtained his M.S. degree in Pharmaceutical Manufacturing & Regulatory Affairs from Stevens Insititute of Technology.
Danielle Armas, M.D.
Senior Principal Investigator Of Gout Clinical Project
· M.D. from Myo Clinic College of Medicine
· Clinical Assistant Professor at University of Arizona, College of Medicine
· 8 years in Principal Investigator, Principal Investigator II and Senior Principal Investigator at Celerion
Mike Li, M.S.
Senior Director, CMC & Regulatory
· M.S. in Chemistry & Chemical Engineering
· Former Sr Director of US Pharmas
· 35 years experience in CMC development
· Preparation of CMC for US IND submission Tech transfer & GMP compliance
Head of Clinical DMPK
· Former Head of DMPK at Roche, CA
· Senior Director and Director of DMPK at UCB Pharma, Adolor and Syntex Research
· Over 30 years of experience in Clinical DMPK
· Contributed to over 50 lead optimization projects. More than 30 of these have proceeded to clinical testing and also contributed to 4 NDA approvals, with successful drugs in clinical use.